|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||27.76 - 28.02|
|52-week range||24.02 - 29.93|
|PE ratio (TTM)||367.50|
|Earnings date||25 Apr 2018 - 30 Apr 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||31.50|
Dentsply Sirona (XRAY) updated its estimates and assumptions during fiscal 2Q17 and underwent an annual impairment test of goodwill. According to company estimates, the goodwill charges associated with some of its technologies segment businesses, including CAD-CAM imaging and its treatment center, came from impairment. The company recorded nearly $1.1 billion in goodwill impairment charges in 2Q17 and $581 million in 4Q17, for a total of ~$1.67 billion in fiscal 2017. Meanwhile, the company undertook an annual impairment assessment of indefinite-lived intangible assets.
The Retirement Systems of Alabama manages assets that totaled $38.4 billion at Sept. 30, 2016, for state pensions and trusts. RSA also owns a number of prominent real-estate properties, including Manhattan skyscraper 55 Water Street and the Robert Trent Jones Golf Trail, a collection of courses. The manager’s largest investment however is in domestic stocks, and as of Dec. 31 it had $20.7 billion invested in U.S.-traded securities.
As of March 7, 2018, Abbott Laboratories (ABT) was trading at a forward PE (price-to-earnings) ratio of 20.8x, while the stock has a PE ratio of 59x. The forward estimate is lower than the current PE ratio, which reflects the analysts’ expectations for higher company earnings over the next 12 months. To calculate the forward PE for a company, the current stock price of the company is divided by its earnings estimates for the next 12 months.
On March 6, 2018, Abbott Laboratories (ABT) announced that it received FDA (US Food and Drug Administration) approval for its Masters HP 15-mm rotatable mechanical heart valve, which is the first and only heart valve developed for newborns and infants. The trial included patients five years and under who had damaged, diseased, or malfunctioning heart valves. On March 6, 2018, ABT stock rose ~0.86%, whereas Medtronic (MDT), Boston Scientific (BSX), and Edwards Lifesciences (EW), which are the other major players in the structural heart device business, saw gains of ~0.83%, ~0.04%, and ~1.2%, respectively.
Stryker (SYK) is a medical technology company that offers products and services in the areas of orthopedics, medical and surgical, neurotechnology, and spine. Of the 28 analysts covering Stryker in February 2018, 11 of them have given the stock a “strong buy” rating, and eight have given it a “buy.” Seven of them have given it a “hold,” and two have given it a “sell” or lower rating. Of the 25 analysts covering Boston Scientific (BSX) in February 2018, 13 of them have given the stock a “strong buy,” seven have given it a “buy,” and five have given it a “hold.” The mean rating for the stock is 1.7 with a target price of $31.50.
Zacks Industry Outlook Highlights: Abbott, Becton and Dickinson, Stryker, Varian Medical and Boston Scientific
Accuray (ARAY) designs, develops, and commercializes advanced radiosurgery and radiation therapy systems for the treatment of tumors. Accuray’s technologies include the CyberKnife and Tomo Theory systems, which deliver radiosurgery, stereotactic body radiation therapy, and adaptive radiation therapy. In February 2018, three of the seven analysts covering Accuray have given the stock a “buy” or higher rating.
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Covidien and Smith & Nephew, Abbott Labs and Boston Scientific